Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Key Inclusion Criteria:

   - Histologically confirmed, stage IIc-IV epithelial ovarian, fallopian tube or
   peritoneal cancer

   - Platinum-resistant or -sensitive subjects after completing first-line treatment
   (debulking surgery and adjuvant or neoadjuvant treatment with standard of care
   treatment such as carboplatin and paclitaxel). Subjects may have had any number of
   subsequent lines of chemotherapy.

   - Must have evidence of progressive disease with either biochemical (i.e. rising CA-125)
   and/or radiologic progression

   - Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy,
   and be willing to undergo tumor biopsy during treatment

   - Ambulatory with an ECOG 0-1

   - Life expectancy ≥ 6 months

   - Meet protocol-specified laboratory requirements

Key Exclusion Criteria:

   - Eligible for otherwise curative treatment or undergoing concurrent therapy

   - Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g.
   anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically
   targeting T cell co-stimulation) or an IDO inhibitor

   - Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
   in situ, or controlled bladder cancer

   - Clinical ascites

   - Any single lesion greater than or equal to 4 cm (per RECIST v1.1)

   - Malignant bowel obstruction

   - History of autoimmune disease requiring treatment within the last two years (except
   vitiligo or diabetes)

   - Recent history of thyroiditis

   - Presence of a serious acute infection or chronic infection

   - Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)

   - GI condition that might limit absorption of oral agents

   - Other serious intercurrent chronic or acute illness, including myocardial infarction
   or cerebrovascular event within 6 months

   - Ongoing treatment with steroid therapy or other immunosuppressive

   - Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors

   - Receipt of live attenuated vaccines

   - Acute or chronic skin and/or microvascular disorders

   - Edema or lymphedema in the lower limbs > grade 2